GlaxoSmithKline S.A.E (EGX:BIOC)

Egypt · Delayed Price · Currency is EGP

260.03

-13.41 (-4.90%)

At close: Oct 22, 2026

Market Cap	21.72B +263.6%
Revenue (ttm)	3.62B +2.8%
Net Income	194.18M +31.1%
EPS	2.33 +38.8%
Shares Out	83.51M
PE Ratio	111.84
Forward PE	n/a
Dividend	0.75 (0.29%)
Ex-Dividend Date	Jan 12, 2026

Volume	115,186
Open	273.44
Previous Close	273.44
Day's Range	257.21 - 277.50
52-Week Range	55.10 - 609.00
Beta	0.28
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 16, 2026

About GlaxoSmithKline S.A.E

GlaxoSmithKline S.A.E engages in production of pharmaceutical chemicals. The company is involved in manufacture of general and specialty medicines, and vaccines. GlaxoSmithKline S.A.E was founded in 1981 and is based in New Cairo, Egypt. GlaxoSmithKline S.A.E operates as a subsidiary of Glaxo Group Limited. [Read more]

Industry Pharmaceutical Preparations

Founded 1981

Country Egypt

Stock Exchange Egyptian Stock Exchange

Ticker Symbol BIOC

Full Company Profile

Financial Performance

In 2025, GlaxoSmithKline S.A.E's revenue was 3.73 billion, an increase of 24.73% compared to the previous year's 2.99 billion. Earnings were 213.23 million, an increase of 22.56%.

Financial Statements